SCO-792

Product Description

CO-792, an enteropeptidase inhibitor, improves disease status of diabetes and obesity in mice. single oral administration of SCO-792 inhibited plasma branched-chain amino acids (BCAAs) in an oral protein challenge test in mice, indicating in vivo inhibition of enteropeptidase. Repeated treatment with SCO-792 induced reduction in food intake and decrease in body weight in DIO and ob/ob mice. (Sourced from: https://doi.org/10.1111/dom.13799)

Mechanisms of Action: Enteropeptidase Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: SCOHIA PHARMA, Inc.
Company Location:
Company CEO:
Additonal Commercial Interests: None